1-13 of 13
Thomas Cluzeau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS

Open Access
Clinical Trials & Observations
Amy E. DeZern, Sylvain Thepot, Stéphane De Botton, Andrea Patriarca, Dries Deeren, Jose Miguel Torregrose Diaz, Giovanni Marconi, Teresa Bernal del Castillo, Juan Miguel Bergua Burgues, Blanca Xicoy, Anna Jonasova, Amer M. Zeidan, Sophie Dimicoli-Salazar, Célestine Simand, David Valcárcel, María Díez-Campelo, Wanxing Chai-Ho, Lalit Saini, Alice Garnier, Klaus Geissler, Yishai Ofran, Zsolt Nagy, Pramila Krishnamurthy, Michael Lübbert, Grzegorz W. Basak, Hetty E Carraway, David A. Sallman, Uma Borate, Valeria Santini, Victoria Campbell, Pierre Fenaux, Thorsten Braun, Francesco Lanza, Jan Maciej Zaucha, David A Roth, Sofia Paul, Pourab Roy, Michael Kelly, Angela Volkert, Jaime Chisolm, Tanya Abdul Malak, Virginia Klimek, Thomas Cluzeau
Journal: Blood Advances
Blood Adv bloodadvances.2025016229.
https://doi.org/10.1182/bloodadvances.2025016229
Published: 2025
Includes: Supplemental data
Journal Articles

Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase Ib CIMON trial

Open Access
Clinical Trials & Observations
Florent Malard, Sylvain Thepot, Thomas Cluzeau, Martin Carre, Delphine Lebon, Pierre Bories, Ollivier Legrand, Marianne Schwarz, Michael Loschi, Mathieu Meunier, Magalie Joris, Cyrielle Gasc, Juliette Jouve, Benoît Levast, Emilie Plantamura, Emmanuel Prestat, Antoine Sabourin, Beatrice Gaugler, Joel Dore, Christian Récher, Mohamad Mohty
Journal: Blood Advances
Blood Adv bloodadvances.2024015571.
https://doi.org/10.1182/bloodadvances.2024015571
Published: 2025
Includes: Supplemental data
Journal Articles

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

Open Access
Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahme, Sarah Bertoli, Luana Fianchi, Jean-Baptiste Micol, Michele Gottardi, Pierre Peterlin, Sara Galimberti, Xavier Thomas, Giuliana Rizzuto, Olivier Legrand, Michela Rondoni, Emmanuel Raffoux, Giambattista Bertani, Alexis Caulier, Michelina D’Argenio, Caroline Bonmati, Atto Billio, Caroline Lejeune, Barbara Scappini, Arnaud Pigneux, Patrizia Zappasodi, Christan Recher, Francesco Grimaldi, Lionel Ades, Roberto M. Lemoli
Journal: Blood Advances
Blood Adv (2025) 9 (4): 752–758.
https://doi.org/10.1182/bloodadvances.2024014279
Published: 2025
Journal Articles

Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3 -mutated AML: a phase 3b trial

Free
Clinical Trials & Observations
Jorge Sierra, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6441–6450.
https://doi.org/10.1182/bloodadvances.2023009847
Published: 2023
Includes: Supplemental data
Journal Articles

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Free
Clinical Trials & Observations
Raphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, Charles Herbaux, Anne Banos, Pauline Brice, David Sibon, Jean Marc Schiano, Thomas Cluzeau, Kamel Laribi, Ronan Le Calloch, Mathieu Bellal, Baptiste Delapierre, Nicolas Daguindau, Sandy Amorim, Kossi Agbetiafa, Adrien Chauchet, Caroline Besson, Eric Durot, Christophe Bonnet, Ludovic Fouillet, Fontanet Bijou, Olivier Tournilhac, Philippe Gaulard, Marie-Cécile Parrens, Gandhi Damaj
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5733–5742.
https://doi.org/10.1182/bloodadvances.2022008524
Published: 2023
Includes: Supplemental data
Journal Articles

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

Free
Clinical Trials & Observations
Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Jane L. Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Joseph G. Jurcic, Mikkael A. Sekeres, Michael R. Savona, Gail J. Roboz, Dale Bixby, Kate Madigan, Angela Volkert, Kristin Stephens, Qing Kang-Fortner, Kristen Baker, Sofia Paul, Michael McKeown, John Carulli, Matthew Eaton, Graeme Hodgson, Christopher Fiore, Michael J. Kelly, David A. Roth, Eytan M. Stein
Journal: Blood Advances
Blood Adv (2023) 7 (9): 1858–1870.
https://doi.org/10.1182/bloodadvances.2022008806
Published: 2023
Includes: Supplemental data
Journal Articles

Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort

Free
Clinical Trials & Observations
Edmond Chiche, Ramy Rahmé, Sarah Bertoli, Pierre-Yves Dumas, Jean-Baptiste Micol, Yosr Hicheri, Florence Pasquier, Pierre Peterlin, Patrice Chevallier, Xavier Thomas, Michael Loschi, Alexis Genthon, Ollivier Legrand, Mohamad Mohty, Emmanuel Raffoux, Patrick Auberger, Alexis Caulier, Magalie Joris, Caroline Bonmati, Gabrielle Roth-Guepin, Caroline Lejeune, Arnaud Pigneux, Norbert Vey, Christian Recher, Lionel Ades, Thomas Cluzeau
Journal: Blood Advances
Blood Adv (2021) 5 (1): 176–184.
https://doi.org/10.1182/bloodadvances.2020003159
Published: 2021
Includes: Supplemental data
Journal Articles

Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases

Free
Giancarlo Fatobene, Fernanda Volt, Frederico Moreira, Lívia Mariano, Patrice Chevallier, Sabine Furst, Hélène Labussière-Wallet, Régis Peffault de la Tour, Eric Deconinck, Thomas Cluzeau, Nigel Russell, Dimitrios Karakasis, Edouard Forcade, Annalisa Ruggeri, Eliane Gluckman, Vanderson Rocha
Journal: Blood Advances
Blood Adv (2020) 4 (24): 6327–6335.
https://doi.org/10.1182/bloodadvances.2020002258
Published: 2020
Includes: Supplemental data
Journal Articles

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Free
Clinical Trials & Observations
Claude Gardin, Cécile Pautas, Elise Fournier, Raphaël Itzykson, Emilie Lemasle, Jean-Henri Bourhis, Lionel Adès, Jean-Pierre Marolleau, Jean-Valère Malfuson, Lauris Gastaud, Emmanuel Raffoux, Juliette Lambert, Thorsten Braun, Xavier Thomas, Sylvain Chantepie, Thomas Cluzeau, Stéphane de Botton, Céline Berthon, Nicolas Boissel, Nicolas Duployez, Christine Terré, Régis Peffault de Latour, Mauricette Michallet, Karine Celli-Lebras, Claude Preudhomme, Hervé Dombret
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1942–1949.
https://doi.org/10.1182/bloodadvances.2019001349
Published: 2020
Includes: Supplemental data
Journal Articles

Non-del(5q) myelodysplastic syndromes–associated loci detected by SNP-array genome-wide association meta-analysis

Free
Kathy L. McGraw, Chia-Ho Cheng, Y. Ann Chen, Hsin-An Hou, Björn Nilsson, Giulio Genovese, Thomas Cluzeau, Andrea Pellagatti, Bartlomiej P. Przychodzen, Mar Mallo, Leonor Arenillas, Azim Mohamedali, Lionel Adès, David A. Sallman, Eric Padron, Lubomir Sokol, Chimene Moreilhon, Sophie Raynaud, Hwei-Fang Tien, Jacqueline Boultwood, Benjamin L. Ebert, Francesc Sole, Pierre Fenaux, Ghulam J. Mufti, Jaroslaw P. Maciejewski, Peter A. Kanetsky, Alan F. List
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3579–3589.
https://doi.org/10.1182/bloodadvances.2019000922
Published: 2019
Includes: Supplemental data
Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Free
Clinical Trials & Observations
Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet
Journal: Blood Advances
Blood Adv (2018) 2 (16): 2063–2071.
https://doi.org/10.1182/bloodadvances.2018015529
Published: 2018
Includes: Supplemental data
Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Free
Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1765–1772.
https://doi.org/10.1182/bloodadvances.2018019414
Published: 2018
Journal Articles

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Free
Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John D. Barnard, Nikolai A. Podoltsev, Andrew M. Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T. Fathi, Gail J. Roboz, Pierre Fenaux, Mark R. Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (8): 923–932.
https://doi.org/10.1182/bloodadvances.2018016121
Published: 2018
Includes: Supplemental data